Skip to main content

Advertisement

SpringerLink
Log in

Amyotrophic lateral sclerosis: Clinical management and research update

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that selectively affects the motor neurons of the brain and spinal cord. ALS occurs in about 1 in 100,000 individuals. Although recent advances have been made in understanding the pathogenesis of ALS, there has been no new effective pharmacotherapy since the approval of riluzole more than 10 years ago. The mainstay of clinical management includes pharmacologic management of symptoms, management of dysphagia and respiratory symptoms, palliative care, and multidisciplinary care clinics. In this review, we discuss the clinical management of ALS, recent modifications to the diagnostic criteria, and current clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Rowland LP: How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean Martin Charcot. Arch Neurol 2001, 58:512–515.

    Article  PubMed  CAS  Google Scholar 

  2. Rosen DR, Siddique T, Patterson D, et al.: Mutations in the Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59–62.

    Article  PubMed  CAS  Google Scholar 

  3. Deng HX, Hentati A, Trainer JA, et al.: Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 1993, 261:1047–1051.

    Article  PubMed  CAS  Google Scholar 

  4. Gurney ME, Pu H, Chiu AY, et al.: Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264:1772–1775.

    Article  PubMed  CAS  Google Scholar 

  5. Bedlack RS, Traynor BJ, Cudkowicz ME: Emerging disease modifying therapies for the treatment of motor neuron disease/amyotrophic lateral sclerosis. Expert Opin Emerg Drugs 2007, 12:229–252.

    Article  PubMed  CAS  Google Scholar 

  6. Ryu H, Ferrante RJ: Translational therapeutic strategies in amyotrophic lateral sclerosis. Mini Rev Med Chem 2007, 7:141–150.

    Article  PubMed  CAS  Google Scholar 

  7. Rowland LP, Schneider NA: Amyotrophic lateral sclerosis. N Engl J Med 2001, 344:1688–1700.

    Article  PubMed  CAS  Google Scholar 

  8. Lomen-Hoerth C: Amyotrophic lateral sclerosis from bench to bedside. Semin Neurol 2008, 28:205–211.

    Article  PubMed  Google Scholar 

  9. Ringholz GM, Appel SH, Bradshaw M, et al.: Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005, 65:586–590.

    Article  PubMed  CAS  Google Scholar 

  10. Radunovic A, Mitsumoto H: Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurol 2007, 6:913–925.

    Article  PubMed  Google Scholar 

  11. World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease: The El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994, 124(Suppl):96–107.

    Google Scholar 

  12. World Federation of Neurology Research Group on Motor Neuron Diseases: El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Available at http://www.wfnals.org/guidelines/1998elescorial/elescorial1998.htm. Accessed November 13, 2008.

  13. de Carvalho M, Dengler R, Eisen A, et al.: Electrodiagnostic criteria for diagnosis of ALS. Clinical Neurophysiol 2008, 119:497–503.

    Article  Google Scholar 

  14. Winhammar JM, Rowe DB, Henderson RD, Kiernan MC: Assessment of disease progression in motor neuron disease. Lancet Neurol 2005, 4:229–238.

    Article  PubMed  Google Scholar 

  15. Czaplinski A, Yen AA, Appel SH: Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry 2006, 77:390–392.

    Article  PubMed  CAS  Google Scholar 

  16. Millul A, Beghi E, Logroscino G, et al.: Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology 2005, 25:114–119.

    Article  PubMed  CAS  Google Scholar 

  17. Millder RG, Rosenberg JA, Gelinas DF, et al.: Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999, 52:1311–1323.

    Google Scholar 

  18. Andersen PM, Borasio GD, Dengler R, et al.: Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler 2007, 8:195–213.

    Article  PubMed  Google Scholar 

  19. Van den Berg JP, Kalmijn S, Lindeman E, et al.: Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 2005, 65:1264–1267.

    Article  PubMed  Google Scholar 

  20. Chio A, Bottacchi E, Buffa C, et al.: Positive effects of tertiary centers for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry 2006, 77:948–950.

    Article  PubMed  CAS  Google Scholar 

  21. Bensimon G, Lacomblez L, Meininger V: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994, 330:585–591.

    Article  PubMed  CAS  Google Scholar 

  22. Lacomblez L, Bensimon G, Leigh PN, et al.: A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology 1996, 47:242s–250s.

    Google Scholar 

  23. Miller RG, Mitchell JD, Lyon M, Moore DH: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2002, (2):CD001447.

  24. Melo J, Homm A, Iturriaga E, et al.: Pulmonary evaluation and prevalence of non-invasive ventilation in patients with amyotrophic lateral sclerosis: a multicenter survey and proposal of pulmonary protocol. J Neurol Sci 1999, 169:114–117.

    Article  PubMed  CAS  Google Scholar 

  25. Jackson CE, Rosenfeld J, Moore DH, et al.: A preliminary evaluation of prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci 2001, 191:75–78.

    Article  PubMed  CAS  Google Scholar 

  26. Lechtzin N, Wiener CM, Shade DM, et al.: Spirometry in the supine position improves the detection of diaphragmatic weakness in patients with amyotrophic lateral sclerosis. Chest 2002, 121:436–442.

    Article  PubMed  Google Scholar 

  27. Lyall RA, Donaldson N, Polkey MI, et al.: Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001, 124:2000–2013.

    Article  PubMed  CAS  Google Scholar 

  28. Bourke SC, Tomlinson M, Williams TL, et al.: Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006, 5:140–147.

    Article  PubMed  Google Scholar 

  29. Mustfa N, Walsh E, Bryant V, et al.: The impact of noninvasive ventilation on the quality of life of ALS patients and their caregivers. Neurology 2006, 66:1218–1222.

    Article  Google Scholar 

  30. Kasarkis EJ, Scarlata D, Hill R, et al.: A retrospective study of percutaneous endoscopic gastrostomy (PEG). Clin Nutr 2005, 24:848–861.

    Article  Google Scholar 

  31. Mazzini L, Corra T, Zaccala M, et al.: Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol 1995, 242:695–698.

    Article  PubMed  CAS  Google Scholar 

  32. Siddique TS, Nijhawan D, Hentati A: Molecular genetic basis of familial ALS. Neurology 1996, 47:S27–S35.

    PubMed  CAS  Google Scholar 

  33. Kauffmann P, Thompson JL, Levy G, et al.: Is a phase III trial of coenzyme Q10 for ALS justified? Results of the phase II randomized controlled trial of COQ10 in ALS [abstract s29.005]. Presented at the 60th Annual Meeting of the American Academy of Neurology. Chicago; April 12–19, 2008.

  34. Groenveld G, Veldink J, Van Der Tweel I, et al.: A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003, 53:437–445.

    Article  CAS  Google Scholar 

  35. Gordon PH, Cheung Y-K, Levin B, et al.: Combination drug selection trial in amyotrophic lateral sclerosis [abstract C77]. Presented at the 18th International Symposium on ALS/MND. Toronto; December 1–3, 2007.

  36. Gordon PH, Moore DH, Miller RG, et al.: Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase II randomized trial. Lancet Neurol 2007, 6:1045–1053.

    Article  PubMed  CAS  Google Scholar 

  37. Cudkowicz ME, Andrews PL, Choudry R, et al.: Safety and dose escalating study of oral sodium phenylbutyrate in subjects with ALS [abstract]. Neurology 2007, 68(Suppl 1):A90.

    Google Scholar 

  38. Meyer T, Maier A, Borisow N, et al.: Thalidomide causes sinus bradycardia in ALS. J Neurol 2008, 255:587–591.

    Article  PubMed  CAS  Google Scholar 

  39. Piepers S, De Jong S, Veldnik JH, et al.: A randomized, placebo controlled, sequential trial of valproic acid in ALS [abstract P04.085]. Presented at the 60th Annual Meeting of the American Academy of Neurology. Chicago; April 12–19, 2008.

  40. Yoshino H, Kimura A: Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph Lateral Scler 2006, 7:241–245.

    Article  PubMed  CAS  Google Scholar 

  41. Cudkowicz ME, Shefner JM, Simpson E, et al.: Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve 2008, 38:837–844.

    Article  PubMed  CAS  Google Scholar 

  42. Gordon PH, Doorish C, Montes J, et al.: Randomized, controlled phase II trial of glatiramer acetate in ALS. Neurology 2006, 66:1117–1119.

    Article  PubMed  CAS  Google Scholar 

  43. Zhang Y, Zhao H, Zhang J, et al.: Investigation of the therapeutic effects of granulocyte colony stimulating factor (G-CSF) in patients with amyotrophic lateral sclerosis: a pilot study [abstract P128]. Presented at the 18th International Symposium on ALS/MND. Toronto; December 1–3, 2007.

  44. Fornai F, Longone P, Cafaro L, et al.: Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008, 105:2052–2057.

    Article  PubMed  CAS  Google Scholar 

  45. Fricker-Gates RA, Shin JJ, Tai CC, et al.: Late stage immature neocortical neurons reconstruct interhemispheric connections and form synaptic contacts with increased efficiency in adult mouse cortex undergoing targeted neurodegeneration. J Neurosci 2002, 22:4045–4056.

    PubMed  CAS  Google Scholar 

  46. Clowry G, Sieradzan K, Vrbova G: Transplants of embryonic motoneurones to adult spinal cord: survival and innervation abilities. Trends Neurosci 1991, 14:355–357.

    Article  PubMed  CAS  Google Scholar 

  47. Mazzini L, Fagioli F, Boccaleti R, et al.: Stem cell therapy in amyotrophic lateral sclerosis: a methodologic approach to humans. Amyotroph Lateral Scler Other Motor Neuron Disord 2003, 4:133–134.

    Article  Google Scholar 

  48. Dimos JT, Rodolfa KT, Niakan KK, et al.: Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321:1218–1221.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Neurological Institute of New York, 710 West 168th Street, New York, NY, 10032, USA

    Jinsy Andrews

Authors
  1. Jinsy Andrews
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jinsy Andrews.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Andrews, J. Amyotrophic lateral sclerosis: Clinical management and research update. Curr Neurol Neurosci Rep 9, 59–68 (2009). https://doi.org/10.1007/s11910-009-0010-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-009-0010-0

Keywords

Search

Navigation